Efti plus Keytruda and chemo achieved a 61% response rate in first-line advanced non-squamous non–small cell lung cancer, ...

Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though ...

Even after many cancer-free years, the fear of recurrence still lingers, and many long-term survivors struggle to keep those ...

CX-2051 treatment demonstrated responses in patients with advanced, late-line colorectal cancer, according to interim data ...

The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met ...